The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...
Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.
A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced ...
Results that may be inaccessible to you are currently showing.